文献速递新发突发、热带与寄生虫病

Ad26.ZEBOV与MVA-BN-Filo两剂异源埃博拉疫苗的安全性与免疫原性:乌干达和坦桑尼亚1期随机临床试验12个月数据

Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania.
PubMed 文献 · J Infect Dis · 2019-01-01

未报告疫苗相关严重不良事件,最常见局部和全身不良事件为注射部位疼痛和头痛。第二剂后21天,100%志愿者产生针对埃博拉病毒糖蛋白的结合抗体,87%-100%产生中和抗体。

要点

  • 异源两剂Ad26.ZEBOV/MVA-BN-Filo方案在健康成人中耐受良好,未报告疫苗相关严重不良事件。
  • 第二剂后21天,100%志愿者产生结合抗体,87%-100%产生中和抗体。
  • Ad26.ZEBOV首剂诱导的初期结合抗体和细胞免疫应答比MVA-BN-Filo首剂更强。

核心结论

  • Ad26.ZEBOV和MVA-BN-Filo异源两剂埃博拉疫苗接种在健康志愿者中耐受良好且具有免疫原性。

主要发现

  • 未报告疫苗相关严重不良事件。
  • 最常见征集性局部和全身不良事件为注射部位疼痛(MVA-BN-Filo、Ad26.ZEBOV和安慰剂每剂频率分别为70%、66%和42%)和头痛(分别为57%、56%和46%)。
  • 第二剂后21天,100%志愿者产生针对埃博拉病毒糖蛋白的结合抗体应答,87%-100%产生中和抗体应答。
  • Ad26.ZEBOV首剂接种诱导的初期结合抗体和细胞应答比MVA-BN-Filo首剂接种更强。

临床怎么用

  • 该异源两剂方案在健康成人中安全且免疫原性强,支持进一步评估其用于埃博拉病毒病预防。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ebola vaccine development was accelerated in response to the 2014 Ebola virus infection outbreak. This phase 1 study (VAC52150EBL1004) assessed safety, tolerability, and immunogenicity of heterologous 2-dose Ad26.ZEBOV, MVA-BN-Filo vaccination regimens in the Lake Victoria Basin of Tanzania and Uganda in mid-level altitude, malaria-endemic settings. METHODS: Healthy volunteers aged 18-50 years from Tanzania (n = 25) and Uganda (n = 47) were randomized to receive placebo or active vaccination with Ad26.ZEBOV or MVA-BN-Filo (first vaccination), followed by MVA-BN-Filo or Ad26.ZEBOV (second vaccination) dose 2, respectively, with intervals of 28 or 56 days. RESULTS: Seventy-two adults were randomized to receive vaccine (n = 60) or placebo (n = 12). No vaccine-related serious adverse events were reported. The most frequent solicited local and systemic adverse events were injection site pain (frequency, 70%, 66%, and 42% per dose for MVA-BN-Filo, Ad26.ZEBOV, and placebo, respectively) and headache (57%, 56%, and 46%, respectively). Adverse event patterns were similar among regimens. Twenty-one days after dose 2, 100% of volunteers demonstrated binding antibody responses against Ebola virus glycoprotein, and 87%-100% demonstrated neutralizing antibody responses. Ad26.ZEBOV dose 1 vaccination induced more-robust initial binding antibody and cellular responses than MVA-BN-Filo dose 1 vaccination. CONCLUSIONS: Heterologous 2-dose vaccination with Ad26.ZEBOV and MVA-BN-Filo against Ebola virus is well tolerated and immunogenic in healthy volunteers. CLINICAL TRIALS REGISTRATION: NCT02376400.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Anywaine Z, Whitworth H, Kaleebu P, et al. Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania. J Infect Dis. 2019. PMID: 30796818. doi:10.1093/infdis/jiz070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。